Search

Displaying results 2121 - 2130 of 2955 in total
  1. Drug

    Glucose-6-Phosphate

    go.drugbank.com/drugs/DB03581
    Experimental

    (Stedman, 26th ed)

  2. Drug

    Daleuton

    go.drugbank.com/drugs/DB00154
    InvestigationalNutraceutical

    A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.

  3. Drug

    Ofatumumab

    go.drugbank.com/drugs/DB06650
    ApprovedInvestigational

    [A6921] Ofatumumab was first approved by the FDA in 2009. … [L12753] The FDA subsequently approved ofatumumab for the treatment of RMS on August 20, 2020.

  4. Drug

    Brilliant blue G

    go.drugbank.com/drugs/DB15594
    Approved

    It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830]

  5. Drug

    Kappadione

    go.drugbank.com/drugs/DB09332
    Approved

    Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is

  6. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368]

  7. Drug

    Elamipretide

    go.drugbank.com/drugs/DB11981
    ApprovedInvestigational

    Food and Drug Administration (FDA) granted accelerated approval for FORZINITY™ (elamipretide) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.

  8. Drug

    Tiotropium

    go.drugbank.com/drugs/DB01409
    ApprovedInvestigational

    [A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]

  9. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory

  10. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune

    Synonyms: (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile